[1] [1] KLONOFF D C. A review of continuous glucose monitoring technology ［J］. Diabetes Technology & Therapeutics, 2005,7(5):770-775.

[2] [2] MITRAGOTRI S, COLEMAN M, KOST J, et al.. Analysis of ultrasonically extracted interstitial fluid as a predictor of blood glucose levels ［J］. Journal of Applied Physiology, 2000,89(3):961-966.

[3] [3] TIESSEN R G, RHEMREV-BOOM M M, KORF J. Glucose gradient differences in subcutaneous tissue of healthy volunteers assessed with ultraslow microdialysis and a nanolitre glucose sensor ［J］. Life Sciences, 2002, 70(21):2457-2466.

[4] [4] GARG S K, POTTS R O, ACKERMAN N R, et al.. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes ［J］. Diabetes Care, 1999,22(10):1708-1714.

[5] [5] GUERCI B, FLORIOT M, BOHME P, et al.. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs ［J］. Diabetes Care, 2003,26(3):582-589.

[6] [6] BURGE M R, MITCHELL S, SAWYER A, et al.. Continuous glucose monitoring: the future of diabetes management ［J］. Diabetes Spectrum, 2008,21(2):112-119.

[7] [7] BECK R W, HIRSCH I B, LAFFEL L, et al.. The effect of continuous glucose monitoring in well-controlled type 1 diabetes ［J］. Diabetes Care, 2009,32(8):1378-1383.

[8] [8] TAMBORLANE W V, BECK R W, BODE B W, et al.. Continuous glucose monitoring and intensive treatment of type 1 diabetes ［J］. The New England Journal of Medicine, 2008,359(14):1464-1476.

[9] [9] MITRAGOTRI S. Synergistic effect of enhancers for transdermal drug delivery ［J］. Pharmaceutical Research, 2000,17(11):1354-1359.

[10] [10] KOST J, MITRAGOTRI S, GABBAY R A, et al.. Transdermal monitoring of glucose and other analytes using ultrasound ［J］. Nature Medicine, 2000,6:347-350.